Here Are 4 Significantly Undervalued Stocks, According to Analysts

A common signal: significant discounts compared to analysts' targets

S.E.B., ARGAN, SOPRA STERIA GROUP, and BIOMERIEUX share a common trait: analysts predominantly issue positive recommendations (buy or outperform), with average target prices ranging from +24.6% to +49.3% above current levels.

S.E.B. shows the highest gap, with an average target of €70.75, representing nearly a 49% potential increase compared to its price of €47.18 — all three of its recommendations being buys. Sopra Steria follows with an average target of €182.25 (+44.6%), although two out of four analysts are more cautious.
Technically, all four stocks are trading below their 200-day moving average, which could indicate a persistent discount zone.
ARGAN's RSI at 30 is at the threshold of the oversold zone, a level to watch for a potential reversal signal. The RSI for S.E.B. (47) and Sopra Steria (49) remain in neutral territory, while bioMérieux shows an RSI of 43, indicating moderate selling pressure. However, today's session shows renewed dynamism: S.E.B. is up 5.78%, ARGAN 6.9%, Sopra Steria 3.27%, and bioMérieux 1.53%.

Contrasting Fundamental and Sector Profiles

Despite this shared value signal, the four stocks have very different fundamental characteristics. S.E.B., a specialist in home appliances (P/E ratio of 10.02), and SOPRA STERIA GROUP, a player in digital services (P/E ratio of 8.06), show valuation multiples significantly below the market average, reinforcing their value profile. ARGAN, a real estate company specializing in logistics (P/E ratio of 4.92), has the lowest ratio in the group, in a real estate sector under pressure. BIOMERIEUX stands out with a higher P/E ratio of 27.40, typical of the health sector, but benefits from a favorable consensus (4 buy recommendations out of 5) and an average target price of €120.50 (+28.7%).
The timetable is a potential catalyst: S.E.B. and bioMérieux release their first-quarter revenue on April 23, Sopra Steria on April 29. ARGAN will not release its next results until July. These dates could be areas of interest for investors attentive to fundamentals.

This article is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.